跳至主要内容
临床试验/CTRI/2011/12/002237
CTRI/2011/12/002237已完成4 期

A Randomized, Open Label, Multicentre, Parallel-Group, Four Arm, Study Comparing Safety and Efficacy of Tacrolimus Topical Ointment (Bioconâ??s Formulation) Versus Protopic® Topical Ointment (Astellas Pharma) in Children and Adults with Atopic Dermatitis - Race

Biocon Limited0 个研究点目标入组 378 人开始时间: 待定最近更新:

试验速览

阶段
4 期
状态
已完成
入组人数
378

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Male or female patients aged between 2 -75 years
  • Patients diagnosed with atopic dermatitis as per Hanifin and Rajka diagnostic standards
  • Patient/parents/guardian is capable of understanding the purposes and risks of the trial and has given written Informed Consent
  • Patient has documented evidence that they have been unresponsive to alternative traditional therapies such as topical corticosteroids, or in the investigators opinion, such first line therapy would be deemed inadvisable because of potential risks to the patient.
  • Patients with an IGA score of 3 (moderate) or 4 (severe) at the time of screening
  • Patients with Eczema Area and Severity Index (EASI) score of at least 15 at the time of screening
  • Treatment naive patients and/or patients receiving treatments for atopic dermatitis other than tacrolimus can be included in the study after 3 days of wash out period
  • Female patients of child bearing potential, using double barrier method or use a reliable method of contraception during the study

排除标准

  • Patient has clinically infected atopic dermatitis at baseline
  • Patient with known hypersensitivity to macrolides in general, to tacrolimus or any excipients of the ointment
  • Any dermatological condition other than atopic dermatitis that in the Investigators opinion may interfere with the evaluation of the patients atopic dermatitis
  • Patients using non-sedating anti-histamines 7 days prior to the first dosing day or at any point during the study
  • Current diagnosis or history or any disease, which in the Investigators opinion would contraindicate the use of immunosuppressantâ??s, including but not limited to human immunodeficiency virus (HIV) and cancer.
  • Females who are pregnant, lactating or likely to become pregnant during the study

研究者

相似试验